{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:21:31Z","timestamp":1790842891091,"version":"4.1.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00176","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T13:21:54Z","timestamp":1553606514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":88,"title":["The Emergence of Universal Immune Receptor T Cell Therapy for Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Nicholas G.","family":"Minutolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Daniel J.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"nri1842","DOI":"10.1038\/nri1842","article-title":"Adoptive immunotherapy for cancer: building on success","volume":"6","author":"Gattinoni","year":"2006","journal-title":"Nat Rev Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science."},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fonc.2014.00063","article-title":"Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE\u00ae antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications","volume":"4","author":"Hoffman","year":"2014","journal-title":"Front Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/nejmoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/nejmoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T Cell Therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2017","journal-title":"Nat Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"sigtrans20162","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Trans Target Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","article-title":"Biology and clinical application of CAR T cells for B cell malignancies","volume":"104","author":"Davila","year":"2016","journal-title":"Int J Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T Cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/jco.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory all","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V128.22.219.219","article-title":"CD19CAR T cell products of defined CD4: CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med."},{"key":"B25","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1182\/blood.V126.23.3433.3433","article-title":"The importance of CD19 exon 2 for Surface Localization: Closing the Ig-like Loop","volume":"126","author":"Bagashev","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.cd-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discovery."},{"key":"B27","doi-asserted-by":"publisher","first-page":"ncomms12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/jci87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/blood-2005-09-3775","article-title":"Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes","volume":"107","author":"Cl\u00e9menceau","year":"2006","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2013","journal-title":"Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/2326-6066.cir-13-0099-t","article-title":"Gene-modified human \u03b1\/\u03b2-T cells expressing a chimeric CD16-CD3\u03b6 receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy","volume":"2","author":"Ochi","year":"2014","journal-title":"Cancer Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jcyt.2015.10.014","article-title":"T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G\u2013opsonized target cells","volume":"18","author":"D'Aloia","year":"2016","journal-title":"Cytotherapy."},{"key":"B38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12967-014-0347-2","article-title":"Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells","volume":"12","author":"Urbanska","year":"2014","journal-title":"J Transl Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1158\/1538-7445.am2017-3768","article-title":"Abstract 3768: CAR T cells specific for CD19 can be redirected to kill CD19 negative tumors","volume":"77","author":"Ambrose","year":"2017","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","article-title":"Redirecting gene-modified t cells toward various cancer types using tagged antibodies","volume":"18","author":"Tamada","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7487","DOI":"10.18632\/oncotarget.23556","article-title":"Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells","volume":"5","author":"Bachmann","year":"2014","journal-title":"Oncotarget."},{"key":"B42","doi-asserted-by":"publisher","first-page":"31368","DOI":"10.18632\/oncotarget.15572","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR.\u201d","volume":"8","author":"Feldmann","year":"2014","journal-title":"Oncotarget."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of genetically engineered CAR-T cells using bifunctional small molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J Am Chem Soc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","article-title":"Versatile strategy for controlling the specificity and activity of engineered T cells","volume":"113","author":"Ma","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B45","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1002\/anie.201601902","article-title":"Design of switchable chimeric antigen receptor T cells targeting breast cancer","volume":"55","author":"Cao","year":"2016","journal-title":"Angewandte Chemie Int Ed."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1287246","DOI":"10.1080\/2162402x.2017.1287246","article-title":"A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform","volume":"6","author":"Albert","year":"2017","journal-title":"OncoImmunology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/gutjnl-2018-316595","article-title":"Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma","author":"Raj","year":"2018","journal-title":"Gut."},{"key":"B50","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5582\/bst.2018.01048","article-title":"Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer","volume":"12","author":"Chu","year":"2018","journal-title":"Biosci Trends."},{"key":"B51","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc National Acad Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/0008-5472.can-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1368604","DOI":"10.1080\/2162402x.2017.1368604","article-title":"mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting","volume":"7","author":"Lohmueller","year":"2017","journal-title":"OncoImmunology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell."},{"key":"B55","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"482089","DOI":"10.1155\/2015\/482089","article-title":"In vitro and in vivo comparison of lymphocytes transduced with a human CD16 or with a chimeric antigen receptor reveals potential off-target interactions due to the IgG2 CH2-CH3 CAR-spacer","volume":"2015","author":"Cl\u00e9menceau","year":"2015","journal-title":"J Immunol Res."},{"key":"B57","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell."},{"key":"B61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-015-0099-4","article-title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","volume":"3","author":"Hammill","year":"2015","journal-title":"J Immu Cancer."},{"key":"B63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-255","article-title":"The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Cancer."},{"key":"B65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/cbr.2009.0627","article-title":"Affinity and avidity in antibody-based tumor targeting","volume":"24","author":"Rudnick","year":"2009","journal-title":"Cancer Biother Amp Radiopharm."},{"key":"B66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nchembio.2565","article-title":"Rewiring T-cell responses to soluble factors with chimeric antigen receptors","volume":"14","author":"Chang","year":"2018","journal-title":"Nat Chem Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00262-010-0844-y","article-title":"Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen","volume":"59","author":"Bluemel","year":"2010","journal-title":"Cancer Immunol Immunother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.ccr-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J Immunother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics."},{"key":"B72","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D'Aloia","year":"2018","journal-title":"Cell Death Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.cd-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discovery."},{"key":"B75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the safety of cell therapy with the TK-suicide gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1182\/blood-2006-05-023416","article-title":"Antitumor effects of HSV-TK\u2013engineered donor lymphocytes after allogeneic stem-cell transplantation","volume":"109","author":"Ciceri","year":"2007","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","article-title":"A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy","volume":"10","author":"Zhang","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Stasi","year":"2011","journal-title":"New Engl J Medicine."},{"key":"B79","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","article-title":"A rapamycin activated caspase 9 based suicide gene","volume":"26","author":"Stavrou","year":"2018","journal-title":"Mol Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"a phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/hgtb.2012.050","article-title":"Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells","volume":"23","author":"Marin","year":"2012","journal-title":"Hum Gene Ther Method."},{"key":"B86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013Based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked chimeric antigen receptor for tumor-specific activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.can-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"21533","DOI":"10.18632\/oncotarget.4071","article-title":"DJ. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity","volume":"6","author":"Song","year":"2015","journal-title":"Oncotarget."},{"key":"B92","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fimmu.2017.00175","article-title":"Antigen loss variants: catching hold of escaping foes","volume":"8","author":"Vyas","year":"2017","journal-title":"Front Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/jci83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest."},{"key":"B95","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B96","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2217\/imt.10.81","article-title":"Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer","volume":"3","author":"Pong","year":"2011","journal-title":"Immunotherapy."},{"key":"B97","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2326-6066.CIR-14-0192","article-title":"T Cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression","volume":"3","author":"Santoro","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr Opin Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/0008-5472.can-12-3913","article-title":"Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice","volume":"73","author":"Chinnasamy","year":"2013","journal-title":"Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.cir-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood."},{"key":"B102","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/cancers8030036","article-title":"Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy","volume":"8","author":"Golubovskaya","year":"2016","journal-title":"Cancers."},{"key":"B103","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature."},{"key":"B105","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.cir-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer immunol Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.4049\/jimmunol.173.12.7125","article-title":"Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy","volume":"173","author":"Robbins","year":"2004","journal-title":"J Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.ccr-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-Cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"B111","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immu Cancer."},{"key":"B113","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-Cell and NK-Cell Infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy","author":"Melero","year":"2014","journal-title":"Cancer Discovery."},{"key":"B114","doi-asserted-by":"publisher","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Reviews."},{"key":"B117","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant negative TGF\u03b2 receptor enhances PSMA targeted human CAR T cell proliferation and augments tumor eradication in prostate cancer","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.can-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:11:27Z","timestamp":1694729487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":119,"alternative-id":["10.3389\/fonc.2019.00176"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00176","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"article-number":"176"}}